PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)74295-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)74295-9/fulltext
Section Title :
Section Order :
219
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74295-9&doi=10.1016/S1098-3015(10)74295-9